A Phase 3 interventional study of AK0529 and Matching placebo of AK0529 in Respiratory Syncytial Virus Infections, sponsored by Shanghai Ark Biopharmaceutical Co., Ltd.. Completed at 28 sites in China. Open to participants aged 1 Month to 24 Months. Per ClinicalTrials.gov, last updated 2024-02-13.
Sponsored by Shanghai Ark Biopharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Respiratory Syncytial Virus Infections with a site in China — 8 open to participants now, 13 under way, 4 of them phase 3. Respiratory Syncytial Virus Infections · China.
Among the 30 studies in Respiratory Syncytial Virus Infections with a site in China, this one is the 10th largest by enrollment of the 25 interventional ones that give a count, is the only one that started in 2020, is one of 6 in phase 3, and was the 2nd registered.
306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.
Browse Respiratory Syncytial Virus Infections studies →8 of the 30 studies in Respiratory Syncytial Virus Infections with a site in China are open now. Recruiting first, the newest first:
Ab&B Bio-tech Co., Ltd.JS · Sites in China
Ages 18+ · Healthy volunteers
Simcere Pharmaceutical Co., Ltd · Sites in China
Ages 1 mo–36 mo
Shanghai Ark Biopharmaceutical Co., Ltd. · Sites in China
Ages 18–85
Kexing Biopharm Co., Ltd. · Sites in China
Ages 2 mo–2 yrs
Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Sites in China
Ages 18–45 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.
This study: 1 Month to 24 Months · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 13 · Phase 3 10
First in 2019; this study’s year is marked. 1 started in 2020.
This study's enrollment of 311 is above the median of 89 across 223 interventional studies indexed under Respiratory Syncytial Virus Infections.
Median enrollment 132 across the 25 interventional studies, 816 across the 5 observational. Of the 17 that completed or were terminated, 5 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 30 have an industry lead sponsor. The 10 most frequent:
Shanghai Ark Biopharmaceutical Co., Ltd. is the lead sponsor of 20 studies on the registry; 2 are open to participants now.
Shanghai Ark Biopharmaceutical Co., Ltd. has 7 studies filed under Respiratory Syncytial Virus Infections — fewer than ten, so there is no comparison to draw.
4 of the studies in Respiratory Syncytial Virus Infections with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07402512Phase 3Simcere Pharmaceutical Co., LtdA Phase III Study of Deuremidevir Hydrobromide for the Treatment of RSV Infection in Infants and Young Children | 2027-03-31 |
| NCT06363370Phase 3Kexing Biopharm Co., Ltd.Human Interferon α1b Inhalation Solution Against Respiratory Syncytial Virus in Children With Lower Respiratory Tract Infections | 2027-06-30 |
| NCT06645665Shenzhen Shenxin Biotechnology Co., LtdA Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adult Aged 18 Years and Above | 2027-04 |
| NCT07582796Ab&B Bio-tech Co., Ltd.JSClinical Trial of Recombinant RSV Vaccine (CHO Cell) (Adjuvanted) in Chinese Population Aged 18 Years and Older. | 2027-09-14 |
Add all 4 to your calendar (.ics) → With an account.
Among the 30 studies in Respiratory Syncytial Virus Infections with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind, placebo-controlled, multicenter, phase III study to be conducted in infants hospitalized with RSV infection in China. The main objectives of this study are to investigate the efficacy and safety of AK0529 in Chinese infants.
Main Inclusion Criteria:
Main Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who are randomized to the experimental arm will receive AK0529 twice daily for five days .
Drug: AK0529
Participants in the control arm will be administered placebo at the matching dosage levels of active medications.
Drug: Matching placebo of AK0529
AK0529 capsule will be orally administered at the twice-daily dosing levels of 10 mg, 20 mg, or 40 mg for five days based on the patient's weight.
Also known as: ziresovir
The placebo capsule was made with the same smell and appearance as AK0529 but without the active ingredients and will be orally administered per the same treatment schedule as those in the experimental arm.
Clinically significant change from baseline in bronchiolitis score on Day 3
To demonstrate that AK0529 is superior to placebo in terms of changes from baseline in bronchiolitis signs and symptoms score. The differences of change in the bronchiolitis score are to be evaluated between the AK0529 and placebo arms after treatment. The total score is reported with a range from 0 to 12. Generally, each score component has a range of values from 0 to 3. A decreasing value of the total score represents a clinical improvement. Unless otherwise noted, the last non-missing measurement/assessment before the first dose of the investigational product is defined as the Baseline measurement. If a measurement/evaluation is performed on the same day of the first dose of the investigational product, these measurements will be considered as Baselines.
Time frame: From Baseline (Pre-dose on Day 1) to Day 3 (48 hours)
Change from baseline in RSV (Respiratory syncytial virus) VL(viral load ) on Day 5
To evaluate the antiviral effects of AK0529. The antiviral effects in infants hospitalized with RSV are to be determined by measuring the differences in viral load determined by RT-PCR between the AK0529 and placebo arms after treatment.
Time frame: From Baseline (Pre-dose on Day 1) to Day 5 (96 hours)
Proportions of subjects with a reduction from baseline in clinical bronchiolitis score ≥ 2 after treatment
Time frame: From Baseline (Pre-dose on Day 1) to Day 14
Proportions of subjects with a reduction from baseline in clinical bronchiolitis score ≥ 3 after treatment
Time frame: From Baseline (Pre-dose on Day 1) to Day 14
Proportions of subjects with a reduction from baseline in clinical bronchiolitis score ≥ 4 after treatment
Time frame: From Baseline (Pre-dose on Day 1) to Day 14
Proportions of subjects with a reduction from baseline in clinical bronchiolitis score ≥ 5 after treatment
Time frame: From Baseline (Pre-dose on Day 1) to Day 14
Proportions of subjects with symptom remission on Day 3 after treatment
Symptom remission is defined as a reduction in clinical bronchiolitis score to 1 or 0 after treatment.
Time frame: Day 3 (48 hours)
Proportions of subjects with symptom remission at other visits after treatment
Symptom remission is defined as a reduction in clinical bronchiolitis score to 1 or 0 after treatment.
Time frame: From Baseline (Pre-dose on Day 1) to Day 14 (except for Day 3)
Proportions of subjects with ≥ 75% reduction from baseline in bronchiolitis score on Day 3 after treatment
Time frame: Day 3 (48 hours)
Proportions of subjects with ≥ 75% reduction from baseline in bronchiolitis score at other visits after treatment
Time frame: From Baseline (Pre-dose on Day 1) to Day 14 (except for Day 3)
Proportions of subjects with disease remission on Day 3 after treatment
Disease remission is defined as a reduction in bronchiolitis score to 1 or 0 after treatment, without non-invasive positive pressure ventilation or assisted mechanical ventilation or supplemental oxygen therapy.
Time frame: From Baseline (Pre-dose on Day 1) to Day 3 (48 hours)
Proportions of subjects with disease remission at other visits after treatment.
Disease remission is defined as a reduction in bronchiolitis score to 1 or 0 after treatment, without non-invasive positive pressure ventilation or assisted mechanical ventilation or supplemental oxygen therapy.
Time frame: From Baseline (Pre-dose on Day 1) to Day 14 (except for Day 3)
Time from the first dose to symptom remission
Symptom remission is defined as a reduction in clinical bronchiolitis score to 1 or 0 after treatment.
Time frame: From Baseline (Pre-dose on Day 1) to Day 14
Time from the first dose to a zero general symptom score for subjects with general symptoms sub-scores equal to 3 at baseline
The General Symptom score is part of the Bronchiolitis Score and has only two scores, 3 and 0. A normal patient is a 0, and the presence of irritable, lethargic, poor feeding is rated as 3.
Time frame: From Baseline (Pre-dose on Day 1) to Day 14
Time from the first dose to a ≥ 75% reduction in bronchiolitis score
Time frame: From Baseline (Pre-dose on Day 1) to Day 14
Time from the first dose to disease remission
Disease remission is defined as a reduction in bronchiolitis score to 1 or 0 after treatment, without non-invasive positive pressure ventilation or assisted mechanical ventilation or supplemental oxygen therapy.
Time frame: From Baseline (Pre-dose on Day 1) to Day 14
Change in bronchiolitis score and percentage change from baseline at each visit after treatment (except Day 3)
Time frame: From Baseline (Pre-dose on Day 1) to Day 14 (except Day 3)
Change from baseline in bronchiolitis sub-score at each visit after treatment
Time frame: From Baseline (Pre-dose on Day 1) to Day 14
Proportions of subjects with the change in bronchiolitis sub-score values at each visit after treatment
Time frame: From Baseline (Pre-dose on Day 1) to Day 14
Proportions of subjects achieving a ≥ 50% reduction from baseline in bronchiolitis score after treatment
Time frame: From Baseline (Pre-dose on Day 1) to Day 14
Proportions of subjects achieving a ≥ 90% reduction from baseline in bronchiolitis score after treatment
Time frame: From Baseline (Pre-dose on Day 1) to Day 14
Respiratory sequelae of subjects from the end of the safety observation period to Month 6
The assessment of respiratory sequelae involves evaluating the frequency, duration, and treatment related to wheezing recurrences and the presence of confirmed asthma.
Time frame: From Day 14 to Month 6
Respiratory sequelae of subjects from the end of the safety observation period to the end of the second year
The assessment of respiratory sequelae involves evaluating the frequency, duration, and treatment related to wheezing recurrences and the presence of confirmed asthma.
Time frame: From Day 14 to end of Year 2
Analysis of subjects admitted to intensive care unit (ICU) for diseases related to RSV infection
Analyzed by the number of admissions, duration of admission, and the duration from the first dose to the end of ICU.
Time frame: From Baseline to the end of ICU
Analysis of subjects receiving non-invasive positive pressure ventilation or assisted mechanical ventilation
Analyzed by the number of subjects receiving non-invasive positive pressure ventilation or assisted mechanical ventilation, duration of such ventilation, and the time from the first dose to the end of assisted ventilation.
Time frame: From Baseline to Day 14
Analysis of subjects receiving supplemental oxygen therapy
Analyzed by the number of subjects receiving supplemental oxygen therapy, duration of such therapy, and the time from the first dose to supplemental oxygen therapy.
Time frame: From first treatment to Day 14
Proportions of subjects with RSV VL below the lower limit of quantification (LLOQ) on Day 5 after treatment
Time frame: Day 5 (96hours)
Proportions of subjects with RSV VL below the LLOQ at other visits
Time frame: From Baseline (Pre-dose on Day 1) to Day 14 (except Day 5)
Change from baseline in RSV VL at each visit except Day 5 after treatment
Time frame: From Baseline (Pre-dose on Day 1) to Day 14 (except Day 5)
Area under the curve of RSV VL from baseline to the last measurement
Time frame: From Baseline (Pre-dose on Day 1) to Day 14
Analysis of clinical efficacy of AK0529 in different subgroups
Analyzed in different subgroups categorized by, at a minimum, months of age, severity of baseline Bronchiolitis Score, time from onset of RSV infection to first dose, RSV viral subtypes, baseline RSV VL classifications, and doses.
Time frame: From Baseline to Day 14
Proportion of subjects with adverse events (AEs) occurring during the study
To evaluate the safety and tolerability of AK0529.
Time frame: From Baseline to Day 14
Proportion of subjects with serious adverse events (SAEs) occurring during the study
To evaluate the safety and tolerability of AK0529.
Time frame: From Baseline to Day 14
Proportion of subjects who withdraw from the study due to AEs during the study
To evaluate the safety and tolerability of AK0529.
Time frame: From Baseline to Day 14
Maximum plasma concentration of AK0529 (Cmax)
PK parameters of AK0529 and its metabolites using population pharmacokinetic (POP-PK) and other appropriate methods.
Time frame: At 3 and 24 hours after the first dose and on Day 6 (120 hours)
Plasma drug trough concentration of AK0529 (Ctrough)
PK parameters of AK0529 and its metabolites using population pharmacokinetic (POP-PK) and other appropriate methods.
Time frame: At 3 and 24 hours after the first dose and on Day 6 (120 hours)
Area under the plasma concentration-time curve from time 0 to infinity (AUC0-inf)
PK parameters of AK0529 and its metabolites using population pharmacokinetic (POP-PK) and other appropriate methods.
Time frame: At 3 and 24 hours after the first dose and on Day 6 (120 hours)
Apparent total body clearance (CL/F)
PK parameters of AK0529 and its metabolites using population pharmacokinetic (POP-PK) and other appropriate methods.
Time frame: At 3 and 24 hours after the first dose and on Day 6 (120 hours)
Apparent volume of distribution (Vz/F)
PK parameters of AK0529 and its metabolites using population pharmacokinetic (POP-PK) and other appropriate methods.
Time frame: At 3 and 24 hours after the first dose and on Day 6 (120 hours)
Elimination half-life (t½)
PK parameters of AK0529 and its metabolites using population pharmacokinetic (POP-PK) and other appropriate methods.
Time frame: At 3 and 24 hours after the first dose and on Day 6 (120 hours)
RSV VL and primary and selected secondary efficacy measurements
To evaluate the relationship of antiviral effects of AK0529 to the primary and key secondary efficacy measurements.
Time frame: From Baseline to Day 14
Selective primary efficacy, secondary efficacy, and safety measures for the pharmacokinetic-pharmacodynamic (PK-PD) analysis
To evaluate the PK-PD correlation between PK parameters and the values of bronchiolitis score and VL, including their respective changes.
Time frame: From Baseline to Day 6
Proportions of subjects with mutations at 20 reported sites associated with RSV fusion inhibitor-resistant mutations in RSV F genesequences after treatment compared to baseline
To sequence the F gene of RSV in nasopharyngeal samples to the monitoring on the development of AK0529 resistance mutation. RSV F gene sequencing was performed with nasopharyngeal samples of subjects using Sanger sequencing.
Time frame: From Baseline to Day 14
Proportions of subjects detected with other respiratory disease-associated viruses at baseline
To detect other common respiratory viruses in nasopharyngeal samples. Detection of respiratory disease-associated viruses includes coronaviruses, adenoviruses, metapneumoviruses, rhinoviruses, enteroviruses, influenza A viruses, influenza B viruses, parainfluenza viruses, and other viruses in baseline nasopharyngeal samples from subjects using microfluidic microarray methods.
Time frame: Baseline (Pre-dose on Day 1)
Changes in respiratory rate during the study
To explore the difference in respiratory rate (bpm) with clinical significance between subjects on AK0529 and those on placebo.
Time frame: From Baseline through Day 6
Changes in heart rate during the study
To explore the difference in heart rate/pulse (bpm) with clinical significance between subjects on AK0529 and those on placebo.
Time frame: From Baseline through Day 6
Changes in body temperature during the study
To explore the difference in body temperature (Celsius) with clinical significance between subjects on AK0529 and those on placebo.
Time frame: From Baseline through Day 6
Changes in systolic blood pressure during the study
To explore the difference in systolic blood pressure (mmHg) with clinical significance between subjects on AK0529 and those on placebo.
Time frame: From Baseline through Day 6
Changes in diastolic blood pressure during the study
To explore the difference in diastolic blood pressure (mmHg) with clinical significance between subjects on AK0529 and those on placebo.
Time frame: From Baseline through Day 6
Changes in SpO2 during the study
To explore the difference in SpO2 (%) with clinical significance between subjects on AK0529 and those on placebo.
Time frame: From Baseline through Day 6
Duration of hospitalization of subjects with RSV infection
To explore the differences in other clinical measurements between subjects on AK0529 and those on placebo.
Time frame: From the day of patient admission to the day of patient discharge
Time from first dose to discharge of subjects with RSV infection
To explore the differences in other clinical measurements between subjects on AK0529 and those on placebo.
Time frame: From Baseline (Day 1) to the day of patient discharge
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2020 to primary completion in Jan 2022, 15 months.
Of 27 industry-sponsored phase 3 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 19. This study's 15 months is above that.
Counting every sponsor, half of 32 studies reached it within 8 months; a quarter within 6 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ziresovir
Respiratory Syncytial Virus Infections →
Shanghai Ark Biopharmaceutical Co., Ltd.